ONCT: Oncternal Therapeutics, Inc. Stock

by  •  • Comments Off on ONCT: Oncternal Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 26.52
Enterprise Value ($M) 19.82
Book Value ($M) 30.05
Book Value / Share 10.15
Price / Book 0.88
NCAV ($M) 29.38
NCAV / Share 9.93
Price / NCAV 0.90

Profitability (mra)
Return on Invested Capital (ROIC) -1.30
Return on Assets (ROA) -0.68
Return on Equity (ROE) -0.75

Liquidity (mrq)
Quick Ratio 6.94
Current Ratio 6.94

Balance Sheet (mrq) ($M)
Current Assets 36.06
Assets 36.73
Liabilities 6.68
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.79
Operating Income -41.71
Net Income -39.48
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -32.16
Cash from Investing 0.65
Cash from Financing 1.07

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Vanguard Group Inc 4.85 -0.11

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-07 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 68 318 21.38
2024-05-02 1,956 374 522.99
2024-05-01 886 567 156.26
2024-04-30 125 533 23.45
2024-04-29 845 710 119.01

(click for more detail)

Similar Companies
OCX – OncoCyte Corporation OKYO – OKYO Pharma Limited
ONCO – Onconetix, Inc. ONCY – Oncolytics Biotech Inc.
ONVO – Organovo Holdings, Inc.


Financial data and stock pages provided by
Fintel.io